Completed the acquisition of Kineta, Inc. and its VISTA inhibiting monoclonal antibody (mAb), now named "TBS-2025;" planning to initiate a Phase 2 trial in relapsed/refractory ...

The pivotal Phase 3 trial for Cylembio® in advanced melanoma showed clinical improvement in progression free survival, but missed its primary endpoint for statistical significance (p=0.056; threshold ...

A research team co-led by UCLA investigators has found that pembrolizumab, an immunotherapy drug that helps the immune system ...

The trial tests BNT113, a biological treatment administered via IV injection, in combination with pembrolizumab, an IV infusion, to enhance therapeutic outcomes for patients with specific head and ...

Immunotherapy employs patients' own immune systems to fight cancer, and it has shown itself to be an effective treatment in ...

Programmed death-1 (PD-1) inhibition with pembrolizumab led to durable remission in 31.3% of patients with early acute ...

Q2 2025 Earnings Call Transcript August 13, 2025 PDS Biotechnology Corporation beats earnings expectations. Reported EPS is $ ...

During a live event, Nataliya Mar, MD, discussed systemic therapies such as lenvatinib/pembrolizumab in advanced renal cell ...

The promising trial results may be a breakthrough for cisplatin-ineligible patients with muscle-invasive bladder cancer.

Cylembio is a therapeutic cancer vaccine candidate that targets cells and immune-suppressive cells in the tumor microenvironment through activation and expansion of T cells against IDO1 and/or PD-L1 ...

No revenue reported as development-stage programs advanced in key clinical trials. These 10 stocks could mint the next wave of millionaires › PDS Biotechnology (NASDAQ:PDSB), a clinical-stage ...

IO Biotech's phase 3 melanoma trial showed a strong PFS benefit, especially in true 1st-line and PD1-negative patients. Click ...